News
Justin Tucker, one of the best kickers in NFL history, suspended for 10 weeks after 16 women said he was sexually ...
Responses cited increasing workloads, shrinking autonomy, mounting interference from hospital administrators and insurance ...
Calling the Iranian regime "evil," Belgium's prime minister reluctantly endorsed the notion of a regime change in Tehran on ...
ICE raids are disrupting worksites across the country, particularly construction sites, as President Trump’s mass deportation ...
Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...
7h
Zacks Investment Research on MSNPFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets GoalPfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating ...
The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...
Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...
Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...
Pfizer announces positive results from phase 3 BASIS study of Hympavzi in haemophilia A or B with inhibitors: New York Friday, June 27, 2025, 10:00 Hrs [IST] Pfizer Inc. announced ...
Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.
In “Sick and Dirty,” author Michael Koresky takes a clear-eyed look at golden age Hollywood’s stealth queerness on screen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results